Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Crohn's Disease

Treatments: Biological: Infliximab

Study type: Observational

Funder types: Industry

Identifiers

NCT00724958

P04052

Details and patient eligibility

About

The current observational program was determined to collect data on the real life dosing regimen of Remicade in patients with Crohn's disease (CD) in the hospital and non-hospital setting.

Full description

This study population was chosen from a non-probability sample

Enrollment: 348 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects with active luminal and/or fistulizing CD.

Exclusion criteria

• Per summary of product characteristics.

Trial design

348 participants in 1 patient group

Remicade

Description:

Subjects with active luminal and/or fistulizing CD in the hospital or non-hospital setting.

Treatment:

Biological: Infliximab